Stryker received FDA 510(k) clearance for its Incompass® Total Ankle System, intended for patients with severe ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

This has positioned BSX as the second-largest player globally, largely due to the rapid adoption of pulsed field ablation ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Intuitive Surgical ISRG entered 2025 with strong operational momentum, delivering 17% year-over-year growth in da Vinci ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our Multi-Factor Investor model based on the published strategy of ...

Investors in Stryker Corp (Symbol: SYK) saw new options become available today, for the August 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SYK ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

America’s new approach to enforcing a decades-old law outlawing foreign bribery means fresh risk for Canadian multinationals, ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company ...